Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-06-11T04:14:45.476Z Has data issue: false hasContentIssue false

X-ray powder diffraction data for ESP15228, C19H34O5, a bempedoic acid metabolite

Published online by Cambridge University Press:  28 April 2023

Massimo Zampieri
Affiliation:
Chemessentia srl, via Bovio 6, Novara 28100, Italy
Guseppe Barreca
Affiliation:
Chemessentia srl, via Bovio 6, Novara 28100, Italy
Norberto Masciocchi*
Affiliation:
Dipartimento di Scienza e Alta Tecnologia and To.Sca.Lab, Università dell'Insubria, via Valleggio 11, Como 22100, Italy
*
a)Author to whom correspondence should be addressed. Electronic mail: norberto.masciocchi@uninsubria.it
Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data, including unit cell parameters and space group assignment, for the ESP15228 species of C19H34O5 formula, are here reported [a = 6.0434(6), b = 12.2543(6), c = 14.0285(8) Å, α = 86.584(3), β = 85.707(10), γ = 78.801(5)°, V = 1015.2(1) Å3, Z = 2, ρcalc = 1.152 g cm−3, and space group P-1]. All measured lines were indexed and no detectable impurities were observed.

Type
Data Report
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

I. INTRODUCTION

The chemical species of C19H34O5 formula (IUPAC name: 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid, sketched in Figure 1) and originally labeled ESP15228 (CAS No. 413624-71-2) is an intermediate compound in the synthesis of bempedoic acid (BA) (Pathy, Reference Pathy2019). BA is a first-in-class medication for the treatment of hypercholesterolemia approved by the US FDA (Food and Drug Administration, 2020) and EMA (European Medical Agency, 2020), and widely marketed with the tradenames of Nexletol, Nexlizet, and Nustendi, among others. ESP15228 is also a known metabolite of the pristine BA drug and was proved to be pharmacologically active.

Figure 1. Molecular diagram of ESP15228.

The analytical characterization of ESP15228 in the solid state requires the identification of crystalline form(s) by conventional X-ray powder diffraction (XRPD) techniques, well beyond phase identification by pattern matching. To this goal, pure batches of ESP15228 were prepared and their XRPD was interpreted by cell determination and peak indexing. Accordingly, in this communication, we provide the detailed list of diffraction peaks, lattice parameters, and space group symmetry, useful for crystal phase recognition and the simultaneous detection of impurity peaks.

II. EXPERIMENTAL

A. Sample preparation

The sample was prepared in Chemessentia's lab, using the following synthetic approach. The corresponding diethyl ester, prepared according to PCT application WO 2020/257573 (Copp et al., Reference Copp, Abdelnasser, Cimarusti and Liu2020), was hydrolyzed by means of aqueous NaOH in ethanol solution. The derived diacid was then crystallized as tiny creamy irregular plates from MTBE/heptane, as per PCT application WO 2004/ 067489 (Dasseux and Oniciu, Reference Dasseux and Oniciu2004). The same crystal form (XRPD evidence) is obtained if crystallization is carried out using an iPrOAc/heptane mixture.

The sample was characterized also by DSC, melting point 82°C (onset); FT-IR peaks, cm−1: 2929, 2904, 2866, 1709, 1690, 1471, 1409, 1191, 947, 881, 783, 765; 1H-NMR (DMSO-d6): 1.18 (m, 8H), 1.42 (m, 8H), 2.37 (t, J = 7.3  Hz, 4H), 1.07 (s, 12H).

B. Diffraction data collection and reduction

Powders of ESP15228 were gently ground in an agate mortar and packed in a 0.2 mm deep sample holder (a silicon zero-background plate). XRPD data collection was performed at 294 K using a D8 Advance diffractometer (Bruker AXS, Karlsruhe, Germany) equipped with a Lynxeye detector and Ni-filtered Cu-Kα radiation (λ CuKα 1 = 1.5406 Å, λ CuKα 2 = 1.5444 Å). The diffraction data were collected in the 3–40° 2θ angular range, sampling at step size Δ2θ = 0.02°, and a counting time of 3 s step−1. HV generator settings, 40 kV, 40 mA; goniometer radius, 250 mm; fixed divergence slit, 0.2 mm; 2.5° Soller slits (2×).

Cell determination (indexing) was attempted using the first 25 observable low-angle peaks, with accurate positions determined by profile fitting methods and the Fundamental Parameters Approach (Cheary and Coelho, Reference Cheary and Coelho1992). These values were fed into the Single Value Decomposition routine (Coelho, Reference Coelho2003) of TOPAS-R, which provided initial triclinic cell parameters: a = 6.05, b = 14.03, c = 19.48 Å, α = 131.3, β = 67.7, γ = 85.7°, V = 1015.7 Å3, GOF(25) = 36.6. All measured lines in the raw data were indexed. Cell reduction to a = 6.05, b = 12.25, c = 14.03 Å, α = 86.6, β = 85.7, γ = 78.8°, was performed with the aid of Wlepage program (Laugier and Bochu, Reference Laugier and Bochu2003).

At this stage, the whole-profile fitting method, using Le Bail technique (Le Bail, Reference Le Bail2005), was employed to fit the 5–40° 2θ range, using a 5th order Chebyshev polynomial as a background trace, a 1/cosθ-dependent Lorentzian broadening (average crystal size = 940 nm) and an additional tanθ-dependent Gaussian broadening accounting for microstrain (<ε 2>1/2 = 0.24). A minor correction for a systematic peak shift, possibly due to sample transparency effects, was also introduced. Final profile agreement factors, for the observed and calculated traces drawn in Figure 2: Rp = 0.051 and R wp = 0.071.

Figure 2. X-ray powder diffraction pattern of ESP15228, collected with Cu-Kα at 294 K (blue line) and the Le Bail simulated pattern (red line), vertically offset for better comparison. Difference plot and peak markers are shown in gray in the bottom section.

III. RESULTS AND DISCUSSION

The Le Bail refinement confirmed that ESP15228 is triclinic with space group P-1 and unit cell parameters a = 6.0434(6), b = 12.2543(6), c = 14.0285(8) Å, α = 86.584(3), β = 85.707(10), γ = 78.801(5)°, unit cell volume V = 1015.2(1) Å3. As per Hofmann's rules (Hofmann, Reference Hofmann2002), the expected molecular volume is 483.2 Å3, indicating Z = 2 and a 1.152 g cm−3 calculated density (for a molecular mass of 342.47 dalton). The values of 2θ obs, d obs, Iobs, h, k, l, 2θ cal, d cal, Δ2θ are listed in Table I. Extraction of peak positions and intensities for reflections falling above 2θ = 27° proved difficult, due to their low(er) intensity, peak widths, and severe overlap. Indeed, while the assignment of hkl triplets to these peaks is possible, it is not an unambiguous procedure and, for the scope of automatic search-matching procedures, of little use. Indeed, the >30 clearly indexed lines provided in Table I, jointly with the unit cell parameters listed above, are considered more than sufficient.

TABLE I. Indexed X-ray powder diffraction data for ESP15228 (d-values calculated by λ CuKα 1 = 1.5406 Å).

Worthy of note, though isostructural to ESP15228, bempenoic acid is not isomorphous with the title compound. Deposited in the CSD database with code IQUXIE (Copp et al., Reference Copp, Abdelnasser, Cimarusti and Liu2020), the crystal structure of the latter species is monoclinic, P21/c, with V = 2075.4 Å3 and Z = 4. This leads to a molecular volume of ca. 519 Å3, slightly larger (as expected) than the 508 Å3 value found for ESP15228. The ca. 11 Å3 difference nicely corresponds to 2 × 5.08 Å3 estimate for the atomic volume of two hydrogen atoms. Noteworthy, the very distinct crystal structures of bempenoic acid and ESP15228 enable their easy fingerprinting, and the detection of one form, as a contaminant, within the other (predominant) crystal phase.

Work can be anticipated in the direction of solving and refining, from powder diffraction data, the unknown structure of ESP15228, which so far resisted solution, due to the molecular flexibility (6 center-of-mass and molecular rotations + 14 torsional angles, neglecting CH3 rotations, using the Z-matrix formalism).

DATA AVAILABILITY

The ESP15228_diffraction_pattern.xy file (ASCII format) has been deposited with ICDD. You may request these data from ICDD at .

ACKNOWLEDGEMENTS

We heartily thank Piero Paravidino and Danilo Giribone for technical assistance and fruitful discussions.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

References

REFERENCES

Cheary, R. W., and Coelho, A.. 1992. “A Fundamental Parameters Approach to X-ray Line-Profile Fitting.” Journal of Applied Crystallography 25: 109. doi:10.1107/s0021889891010804.CrossRefGoogle Scholar
Coelho, A. A. 2003. “Indexing of Powder Diffraction Patterns by Iterative Use of Singular Value Decomposition.” Journal of Applied Crystallography 36: 86. doi:10.1107/S0021889802019878CrossRefGoogle Scholar
Copp, R., Abdelnasser, M., Cimarusti, C. M., and Liu, C.. 2020. “Salt Forms of Bempedoic Acid and Methods for Using the Same,” Patent WO2020257573A1, filed 19 June 2019, and published 24 December 2020. https://patents.google.com/patent/WO2020257573A1/.Google Scholar
Dasseux, J. L. H., and Oniciu, D. C.. 2004. “Hydroxyl Compounds and Compositions for Cholesterol Management and Related Uses,” Patent WO2004067489A2, filed 23 December 2003, and published 18 August 2004. https://patents.google.com/patent/WO2004067489A2/.Google Scholar
European Medical Agency. 2020. “EMEA/H/C/004958”, April 1, 2020.Google Scholar
Food and Drug Administration. 2020. “New Drug Therapy Approvals 2020”, December 31, 2020.Google Scholar
Hofmann, D. W. A. 2002. “Fast Estimation of Crystal Densities.” Acta crystallographica Section B: Structural Science B58: 489. doi:10.1107/S0108768101021814CrossRefGoogle Scholar
Laugier, J., and Bochu, B.. 2003. “‘Windows Interface for the Use of the LePage Pogram’, Freely Adapted from Anthony L. Spek, ‘Single-Crystal Structure Validation with the Program PLATON’.” Journal of Applied Crystallography 36: 7. doi:10.1107/S0021889802022112Google Scholar
Le Bail, A. 2005. “Whole Powder Pattern Decomposition Methods and Applications: A Retrospection.” Powder Diffraction 20: 316. doi:10.1154/1.2135315.CrossRefGoogle Scholar
Pathy, K. S. 2019. “Bempedoic Acid a Small Molecule Drug Process and Synthesis, Innovation and/or Advantages, Development Status and/or Regulatory Status.” Surgery & Case Studies 3: 222. doi:10.32474/SCSOAJ.2019.03.000154.Google Scholar
Figure 0

Figure 1. Molecular diagram of ESP15228.

Figure 1

Figure 2. X-ray powder diffraction pattern of ESP15228, collected with Cu-Kα at 294 K (blue line) and the Le Bail simulated pattern (red line), vertically offset for better comparison. Difference plot and peak markers are shown in gray in the bottom section.

Figure 2

TABLE I. Indexed X-ray powder diffraction data for ESP15228 (d-values calculated by λCuKα1 = 1.5406 Å).